论文部分内容阅读
目的:探讨EGFR、GnRHR和LRP在上皮性卵巢癌中的表达及临床意义。方法:采用免疫组化S-P法检测10例正常卵巢组织、10例卵巢良性上皮性肿瘤和50例上皮性卵巢癌的石蜡包埋标本中EGFR、CmRHR和LRP的表达情况,通过统计学方法分析其表达与临床各种病理因素指标、化疗耐药及患者生存预后的关系。结果:卵巢癌中EGFR、GnRHR和LRP的表达明显高于良性组和正常组,EGFR的表达随着期别的增高而增加。EGFR表达阳性的卵巢癌术后生存率明显低于EGFR阴性表达的患者,LRP和GnRHR表达阳性的患者与表达阴性者生存率差异无统计学意义。EGFR和LRP表达阴性者化疗有效率分别明显高于二者表达阳性者。结论:EGFR在不同分期卵巢癌中的差异性表达也许可作为评判肿瘤恶性程度的指标,并可能成为卵巢癌的治疗新靶点。卵巢癌组织中GnRHR表达的阳性率与癌细胞的分化程度有一定关系,LRP在上皮性卵巢癌中的表达与化疗疗效密切相关,可用于临床预测化疗的敏感性。
Objective: To investigate the expression and clinical significance of EGFR, GnRHR and LRP in epithelial ovarian cancer. Methods: The expression of EGFR, CmRHR and LRP in 10 specimens of normal ovarian tissue, 10 specimens of ovarian benign epithelial tumor and 50 specimens of epithelial ovarian cancer were detected by immunohistochemical SP method. The expression of EGFR, Expression and clinical pathological factors, chemotherapy resistance and prognosis of patients with the relationship. Results: The expression of EGFR, GnRHR and LRP in ovarian cancer was significantly higher than that in benign group and normal group. The expression of EGFR increased with the increase of stage. The postoperative survival rate of patients with positive EGFR expression in ovarian cancer was significantly lower than that in patients with negative expression of EGFR. There was no significant difference in survival between patients with positive expression of LRP and GnRHR and those with negative expression of EGFR. The effective rates of chemotherapy in patients with negative EGFR and LRP expression were significantly higher than those with positive expression of both. Conclusion: The differential expression of EGFR in different stages of ovarian cancer may be used as an indicator of malignancy and may be a new therapeutic target for ovarian cancer. The positive rate of GnRHR expression in ovarian cancer has a certain relationship with the degree of differentiation of cancer cells. The expression of LRP in epithelial ovarian cancer is closely related to the curative effect of chemotherapy, which can be used to predict the sensitivity of chemotherapy.